IL6 and congenital rubella syndrome: In addition, many clinical trials have shown that the use of tocilizumab does not impair therapeutic outcomes.39,94 Therefore, in various CRS management guidelines, tocilizumab is widely accepted and recommended across different CRS grades.95 However, some controversy remains regarding the use of anti-IL-6 agents.